ArticleInternal medicine (Tokyo, Japan)2021

Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy.

Yudai Fujiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.